Neuroimaging and clinical predictors of fatigue in Parkinson disease

Parkinsonism and Related Disorders

Volumn 23, Issue , 2016, Pages 45-49

  Chou, Kelvin L ^a,b   Kotagal, Vikas ^a,c   Bohnen, Nicolaas I ^a,b,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Fatigue; Parkinson disease; PET imaging

Indexed keywords

DIHYDROTETRABENAZINE C 11; METHYL 4 PIPERIDINYL PROPIONATE ACETYLCHOLINESTERASE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ANXIETY; APATHY; ARTICLE; BECK DEPRESSION INVENTORY; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SLEEP; UNIFIED PARKINSON DISEASE RATING SCALE; COMPLICATION; COMPUTER ASSISTED DIAGNOSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; MIDDLE AGED; PROCEDURES;

AGED; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROIMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84960909881     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.11.029     Document Type: Article

References (31)

1. Friedman J.H., Brown R.G., Comella C., et al. Fatigue in Parkinson's disease: a review. Mov. Disord. 2007, 22:297-308.
2. Friedman J., Friedman H. Fatigue in Parkinson's disease. Neurology 1993, 43:2016-2018.
3. Herlofson K., Ongre S.O., Enger L.K., Tysnes O.B., Larsen J.P. Fatigue in early Parkinson's disease. Minor inconvenience or major distress?. Eur. J. Neurol. 2012, 19:963-968.
4. Schifitto G., Friedman J.H., Oakes D., et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008, 71:481-485.
5. Alves G., Wentzel-Larsen T., Larsen J.P. Is fatigue an independent and persistent symptom in patients with Parkinson disease?. Neurology 2004, 63:1908-1911.
6. Herlofson K., Larsen J.P. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol. Scand. 2003, 107:1-6.
7. Lou J.S., Kearns G., Benice T., Oken B., Sexton G., Nutt J. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. Mov. Disord. 2003, 18:1108-1114.
8. Pavese N., Metta V., Bose S.K., Chaudhuri K.R., Brooks D.J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133:3434-3443.
9. Lang A.E. The progression of Parkinson disease: a hypothesis. Neurology 2007, 68:948-952.
10. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
11. Bohnen N.I., Albin R.L., Muller M.L., et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson Disease and evidence of interaction effects. JAMA Neurol. 2015 Feb, 72(2):194-200.
12. Chou K.L., Lenhart A., Koeppe R.A., Bohnen N.I. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Park. Relat. Disord. 2014, 20:1076-1080.
13. Bohnen N.I., Kaufer D.I., Hendrickson R., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J. Neurol. 2006, 253:242-247.
14. Bohnen N.I., Muller M.L., Koeppe R.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73:1670-1676.
15. Petrou M., Bohnen N.I., Muller M.L., Koeppe R.A., Albin R.L., Frey K.A. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012, 79:1161-1167.
16. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
17. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46:1121-1123.
18. Friedman J.H., Alves G., Hagell P., et al. Fatigue rating scales critique and recommendations by the movement disorders society task force on rating scales for Parkinson's disease. Mov. Disord. 2010, 25:805-822.
19. Goetz C.G., Tilley B.C., Shaftman S.R., et al. Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008, 23:2129-2170.
20. Johns M.W. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep 1991, 14:540-545.
21. Bastien C.H., Vallieres A., Morin C.M. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep. Med. 2001, 2:297-307.
22. Beck A.T., Steer R.A., Ball R., Ranieri W. Comparison of beck depression inventories - IA and -II in psychiatric outpatients. J. Pers. Assess. 1996, 67:588-597.
23. Spielberger C.D., Gorsuch R.L., Lushene P.R., Vagg P.R., Jacobs A.G. Manual for the State-trait Anxiety Inventory (Form Y) 1983, Consulting Psychologists Press, Inc., Palo Alto.
24. Marin R.S., Biedrzycki R.C., Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res. 1991, 38:143-162.
25. Bohnen N.I., Muller M.L., Kotagal V., et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J. Cereb. Blood Flow. Metab. 2012, 32:1609-1617.
26. Jewett D.M., Kilbourn M.R., Lee L.C. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl. Med. Biol. 1997, 24:197-199.
27. Snyder S.E., Tluczek L., Jewett D.M., Nguyen T.B., Kuhl D.E., Kilbourn M.R. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl. Med. Biol. 1998, 25:751-754.
28. Nagatsuka Si S., Fukushi K., Shinotoh H., et al. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J. Cereb. Blood Flow. Metab. 2001, 21:1354-1366.
29. 11C]dihydrotetrabenazine. J. Cereb. Blood Flow. Metab. 1999, 19:1376-1384.
30. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
31. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov. Disord. 2001, 16:507-510.